Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.

Methods

A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.

Results

A total of five retrospective studies, representing 863 pati

SUBMITTER: Dekker EN 

PROVIDER: S-EPMC11472162 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature